Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform GlobeNewswire January 12, 2026 Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers of next-generation precision medicines BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Precede Biosciences, a […]

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 GlobeNewswire January 12, 2026 ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 GlobeNewswire January 12, 2026 Company expects preliminary unaudited AUCATZYL(R) net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates full

Noodles & Company Announces Preliminary Revenue Results for the Fourth Quarter of 2025 Company to Host Investor Meetings at 28th Annual ICR Conference GlobeNewswire January 12, 2026 BROOMFIELD, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today released preliminary, unaudited sales results for the fourth fiscal quarter ended December 30, 2025.

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones GlobeNewswire January 12, 2026 On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj(R) (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx(R) VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to

NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026 GlobeNewswire January 12, 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (“NewtekOne”) today announced that the expiration date with respect to its previously announced offer to exchange (the “Exchange Offer”) its outstanding 5.50% Notes due 2026 (the “Old Notes”)

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 GlobeNewswire January 12, 2026 ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and

KEY Investment Partners Acquires BellRock Brands' Portfolio, Home of Mary's Medicinals, Dixie and Other Top Names Company purchased out of receivership to acquire brand assets and provide working capital for growth; former Curaleaf CEO Joe Bayern to serve as CEO GlobeNewswire January 12, 2026 DENVER, Jan. 12, 2026 (GLOBE NEWSWIRE) — KEY Investment Partners announced